Adragos Pharma Expands Drug-Product Capabilities with Key Acquisitions

Cem Goekmen
Head of Corporate Development 
Adragos Pharma

Adragos Pharma has expanded its global footprint with several key recent acquisitions to expand its drug-product development and manufacturing capabilities. Cem Goekmen, Head of Corporate Development, Adragos Pharma, outlined the expansions to the company’s global footprint at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week

Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its strategic goal is to expand its existing production network through acquisitions in Europe, North America, and Japan. The company’s most recent acquisition was completed in February 2024 with the acquisition of  a sterile pharmaceutical production site in Halden, Norway, from Fresenius Kabi. The facility’s capabilities include the production of IV bags, ampoules, blow–fill–seal technology, and other pharmaceutical dosage forms.

The company also made two key acquisitions in 2023 to add to its global network. In 2023, Adragos completed the acquisition of a manufacturing facility in Kawagoe, Japan, from Sanofi. The site, near Tokyo, under Sanofi, manufactured oral solids and ampoules. In addition, the site provided packaging, visual inspection, and QC test services for the Japanese and Asian markets.

Also in 2023, the company completed the acquisition of Lamda Laboratories S.A. in Athens, Greece. Lamda, a CDMO, was formerly part of Clinigen, a global pharmaceutical services provider. The Athens site is Adragos’ flagship development facility and is also equipped with specialized equipment to allow for the handling of highly potent pharmaceuticals. It supports projects from inception and development to supply, including formulation development, analytical services, clinical development and regulatory support.

Post-integration of these acquisitions,  the company now operates five manufacturing sites and has facilities in France, Norway, Germany, Greece, and Japan with approximately 1,300 employees (full-time equivalents). Its acquisitions in Norway, Greece, and Japan in 2023/2024 added to the company’s global footprint and its existing facilities in France and Germany.